eIF4E is a potent oncogene, elevated in 50–100% of approximately 30% of human cancers (e.g., Hodgkin and non-Hodgkin lymphomas, chronic myelogenous leukemia (CML), and subtypes of acute myeloid leukemia (AML), as well as cancers of the breast, prostate, lung, head, and neck (including glioblastoma), and colon (especially those that are human papillomaviruses (HPV)-related)). This evidence concerns the gene EIF4E and chronic myelogenous leukemia, BCR-ABL1 positive.